GRFSGrifols Therapeutics LLCSigning up patients
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Hypogammaglobulinemia · Bacterial Infections · B-cell Chronic Lymphocytic Leukemia · Multiple Myleoma · Non-Hodgkin Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 386 (planned)
- Started
- Dec 26, 2022
- Main results expected
- Aug 2029
- Fully finished
- Aug 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Annual Rate of Major Bacterial Infections per Year
Measured over: Up to Week 51
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05645107 · record last updated 2026-09-30 · checked 2026-11-09 15:42 UTC